ClinicalTrials.gg
CompletedNCT05843578Updated Jul 9, 2026

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

A Phase 2 interventional study of AGMB-129 and Placebo in Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Completed at 52 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
199th of 528
103 · median 60
Started
2023
with 25 others
Phase 2
141 of 660
23 open now
Registered
544th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 199th largest by enrollment of the 528 interventional ones that give a count, is one of 26 that started in 2023, is one of 141 in phase 2, and was the 544th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the safety, pharmacokinetics, and pharmacodynamics of AGMB-129 (Ontunisertib) in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures.

The participants will be in the Part A for a duration of up to 19 weeks including a 5 week screening period, a 12-week double-blind, placebo-controlled treatment period, and 2 week safety follow up period. Participants who continue to Part B can receive treatment for up to an additional 48 weeks, with a safety follow-up visit 2 weeks after the last dose of treatment.

Read the detailed description

Part A is a randomized, placebo-controlled, double-blind, parallel, multicenter, phase 2a study in participants with Crohn's disease and symptomatic intestinal strictures.

Part A consists of 3 periods (a screening period, a placebo-controlled, double-blind treatment period, and safety follow-up). After signing informed consent, eligibility will be assessed during a 5-week screening period. The presence of qualifying intestinal strictures will be assessed by ileocolonoscopy and magnetic resonance enterography (MRE). The presence of obstructive symptoms will be also evaluated.

Eligible participants will be randomized 1:1:1 to receive AGMB-129 high dose, low dose or placebo for 12 weeks.

During Screening and Week 12 visits, participants will undergo ileocolonoscopy with biopsy collection for exploring pharmacodynamics. Participants will have blood sample collection at Weeks 2, 4, 8, and 12 to assess safety, pharmacokinetics, and pharmacodynamics.

Throughout the study, participants will undergo routine safety assessments at study visits, which will include physical examination, vital signs, clinical laboratory assessment, electrocardiogram (ECG), and recording of AEs.

Part B is an open-label treatment extension for participants who have completed the double-blind treatment period in Part A.

03

Conditions studied

  • Fibrostenotic Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part A):

  1. Diagnosis of ileal or ileocolonic CD based on supporting guideline criteria (eg, clinical, endoscopic, and histologic evidence) established at least 3 months prior to screening.
  2. Presence of at least 1 stricture in the terminal ileum within reach of an endoscope (passable or nonpassable).Strictures should be noncritical, naïve or anastomotic stricture(s), caused by CD and confirmed centrally by MRE according to the following criteria:

    • Localized luminal narrowing (luminal diameter ≤50% relative to normal adjacent bowel); AND
    • Bowel wall thickening (≥25% relative to adjacent bowel; AND
    • Either prestenotic dilation (defined as a luminal diameter ≥3 cm) or nonpassable with adult colonoscope
  3. Presence of tolerable obstructive symptoms, as defined by a screening S-PRO severity score ≥2, and not expected to require hospitalization, endoscopic balloon dilation, surgical resection, or additional therapy during the study. Participant should have sufficient food intake, even with diet modification.
  4. Stable background therapy for CD and agree to maintain background therapy for the study duration

Exclusion criteria (Part A):

  1. History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug-induced colitis, idiopathic colitis (ie, colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption.
  2. CD-related complications (previous extensive small bowel resection, ileorectal anastomosis, proctocolectomy, short bowel syndrome, ileostomy [diverting or end], colostomy, small bowel stoma, ileoanal pouch, inactive fistulae in or adjacent to an ileal stricture, anal and perianal stricture, active intra-abdominal or perianal abscess that has not been appropriately treated, abscess in relation to the stricture, toxic megacolon, very severe inflammation, or presence of deep ulceration in the colon or terminal ileum).
  3. Ileitis not associated with CD (eg, ileitis associated with infections, spondyloarthropathies, ischemia, etc.).
  4. Endoscopic balloon dilation or surgical treatment of the same small bowel stricture within the last 6 months prior to screening
  5. Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening or Janus kinase inhibitor therapy within 4 weeks of screening.
  6. Requiring continued treatment with systemically administered medications that are sensitive /5 substrates with a narrow therapeutic index or strong inhibitors of aldehyde oxidase or xanthine oxidase.
  7. Current or history of vasculitis, valvulopathy or large vessel disorder or major abnormalities documented by cardiac echocardiography with Doppler

Inclusion Criteria (Part B):

  1. Completion of the 12-week treatment period (Part A) and participant is willing and able to continue treatment.
  2. Per investigator judgment, participant is able to continue or resume treatment following completion of the Week 12 visit in Part A.

Exclusion criteria (Part B):

  1. More than 24 weeks since completion of the Week 12 visit in Part A.
  2. Experienced any AE leading to permanent treatment discontinuation during treatment with study drug in the double blind treatment period (Part A).
  3. Have undergone endoscopic balloon dilation or bowel surgery (resection surgery or strictureplasty) for any intestinal stricture since the Week 12 visit in Part A.
  4. Developed any condition which meets the Part A exclusion criteria, as per investigator judgment.
  5. Any condition which in the opinion of the investigator affects the safety or ability to participate in Part B.
  6. Participation in any other clinical trial since the completion of the Week 12 visit in Part A.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    AGMB-129 High

    AGMB-129 high dose

    Drug: AGMB-129

  • Experimental
    AGMB-129 Low

    AGMB-129 low dose

    Drug: AGMB-129

  • Experimental
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Oral capsule

  • DrugPlacebo

    Matching oral capsule

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of adverse events at every visit

    Time frame: From Screening to Week 48

  2. Number of participants with abnormal clinical laboratory values (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of abnormal laboratory parameters at every visit

    Time frame: From Screening to Week 48

  3. Number of participants with abnormal ECG parameters (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of abnormal ECG parameters at every visit

    Time frame: From Screening to Week 48

  4. Number of participants with abnormal vital signs (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of vital signs at every visit

    Time frame: From Screening to Week 48

  5. Number of participants with abnormal physical exams (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of physical exams at every visit

    Time frame: From Screening to Week 48

  6. Number of participants with abnormal 2D-echocardiography (Part A and B)

    To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of echocardiography at week 12

    Time frame: From Screening to Week 48

Secondary outcomes

  1. Plasma levels of AGMB-129 and its metabolites (Part A and B)

    To characterize the pharmacokinetics (PK) of AGMB-129 and its metabolites by measuring the amount in plasma

    Time frame: From Baseline to Week 48

  2. Changes in mRNA gene expression in ileal biopsies ((Part A)

    To characterize the pharmacodynamics of AGMB-129 by determining the gene expression in ileal biopsies

    Time frame: From Baseline to Week 48

07

Study locations

52 sites
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Digestive and Liver Center of Florida
    Orlando, Florida 32825, United States
  • Gastroenterology Health Partners
    New Albany, Indiana 47150, United States
  • Gastroenterology Health Partners
    Louisville, Kentucky 40218, United States
  • Louisiana Research Center
    Shreveport, Louisiana 71105, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Gastro One
    Cordova, Tennessee 38018, United States
  • Medical University of Graz
    Graz, 8036, Austria
  • Gemeinnutzige Salzburger Landeskliniken Betriebsgesellschaft mbH (Landeskrankenhaus Salzburg/Regional Hospital Salzburg)
    Salzburg, 5020, Austria
  • Medical University Of Vienna (AKH Wien)
    Vienna, 1090, Austria
  • Hospital Landstrasse, Department of Internal Medicine IV
    Vienna, Austria
  • University of Calgary
    Calgary, AB T2N 4Z6, Canada
  • Gastroenterology and Internal Medicine Research Institute (GIRI)
    Edmonton, T5R1W2, Canada
  • South Edmonton Gastroenterology Research Clinic
    Edmonton, T6K 4B2, Canada
  • Nova Scotia Health Authority
    Halifax, Canada
  • TIDHI Innovation Inc.
    North York, ON M6A 3B4, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Canada
  • (G.I.R.I) GI Research Institute
    Vancouver, BC V6Z 2K5, Canada
  • Aarhus University Hospital, Department of Hepatology and Gastroenterology
    Aarhus, Denmark
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • Rigshospitalet - University Hospital Copenhagen
    Copenhagen, Denmark
  • Herlev Hospital (University of Copenhagen)
    Herlev, 2730, Denmark
  • Odense University Hospital
    Odense, 5000, Denmark
  • Charite Universitatsmedizin Berlin KöR Campus Benjamin Franklin Medizinische
    Berlin, 12203/12200, Germany
  • Servicegesellschaft Krankenhaus Waldfriede mbH Krankenhaus Waldfriede e.V Akademisches Lehrkrankenhaus der Charite
    Berlin, 14163, Germany
  • BSF Studiengesellschaft UG (Unternehmergesellschaft, haftungsbeschränkt)
    Halle, 06108, Germany
  • Universitatsklinikum Ulm AöR (University of Ulm)
    Ulm, 89081, Germany
  • University Polyclinic Hospital "G. Martino"
    Messina, Italy
  • Humanitas Research Hospital IRCCS Istituto Clinico Humanitas
    Milan, 20089, Italy
  • Hospital San Raffaele
    Milan, Italy
  • Azienda Ospedaliero Universitaria di Modena - Struttura Complessa di Gastroenterologia
    Modena, 41124, Italy
  • Sacred Heart Don Calabria
    Negrar, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Rome, 00152, Italy
  • University Polyclinic Foundation "Agostino Gemelli"
    Rome, Italy
  • Specialist Gastrology Centre GASTROMED
    Bialystok, Poland
  • Vita Longa Sp. z.o.o.
    Katowice, 40-748, Poland
  • MEDRISE Sp. z o.o.
    Lublin, 20-582, Poland
  • SOLUMED Medical Center
    Poznan, Poland
  • Endoskopia Sp. z o.o.
    Sopot, Poland
  • H-T. Medical Center
    Tychy, Poland
  • WIP Warsaw IBD Point
    Warsaw, 00-728, Poland
  • WSD Medi Clinical Sp. z o.o.
    Warsaw, Poland
  • Planetmed Sp. z o.o.
    Wroclaw, 52210, Poland
  • VISTAMED
    Wroclaw, Poland
  • ETG Zamość
    Zamość, 22-400, Poland
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de Gran Canaria
    Las Palmas de Gran Canaria, 35010, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jun 2026, 34 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 34 months is close to that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Aug 1, 2023
Primary completionActual
Jun 20, 2026
CompletionActual
Jun 20, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843578
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Aug 1, 2023
Primary completion
Jun 20, 2026
Completion
Jun 20, 2026
Last update
Jul 9, 2026

Study contacts

Philippe Wiesel, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion